Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide phase 2 placebo-controlled trial in nonalcoholic steatohepatitis
MOH_2020-03-09_008517Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Eli Lilly and Company. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2020-03-09_008517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-09_008517.